Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Carcinoma, Basal Cell
Conditions
Brief summary
A group of researchers at the Ontario Cancer Institute/Princess Margaret Hospital have discovered that a very specific form of cell death 'apoptosis' can be detected using high-frequency ultrasound imaging. This type of cell death is recognized to occur in tumours in response to various different chemotherapeutic drugs and in response to radiation therapy. This group of researchers has confirmed that high-frequency ultrasound can detect apoptosis in response to tumour treatments experimentally using cell culture and experimental animal systems. The ultrasound approach is now being evaluated clinically in a 3-year clinical trial enrolling a target of 200 patients including Hodgkin's disease and non-Hodgkin's disease lymphoma patients, melanoma patients and patients with basal cell carcinoma. Our hope is to be able to use this type of imaging system in the future to clinically monitor the effects of therapy on tumours and rapidly detect tumours which are not responding so that changes in therapy can be made much quicker than presently possible.
Interventions
PROCEDUREhigh frequency ultrasound imaging
Sponsors
Princess Margaret Hospital, Canada
University Health Network, Toronto
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* lymphoma patients with superficial lesions prior to starting chemotherapy or after relapse of disease * patients with superficial melanoma lesions * patients with superficial basal cell carcinoma lesions * Informed consent
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility study of the use of Ultrasound Biomicroscopy for monitoring tumour response of lymphoma and melanoma patients to chemotheapy or radiation therapy. | — |
Countries
Canada
Outcome results
None listed